Literature DB >> 33987235

Hemoglobin A1c modifies the association between triglyceride and time in hypoglycemia determined by flash glucose monitoring in adults with type 1 diabetes: implications for individualized therapy and decision-making.

Yiwen Liu1, Jie Yu1, Chifa Ma1, Shuli He2, Fan Ping1, Huabing Zhang1, Wei Li1, Lingling Xu1, Xinhua Xiao1, Yuxiu Li1.   

Abstract

BACKGROUND: We aimed to investigate the associations of flash glucose monitoring (FGM)-derived metrics with lipid profiles and identify potential modifiers of these associations among adults with type 1 diabetes (T1D).
METHODS: A cross-sectional study was conducted among 108 Chinese adults with T1D who used FGM for 14 consecutive days. The relationship between FGM-derived metrics and lipid variables and potential modifiers were identified using interaction and subgroup analysis.
RESULTS: Serum triglyceride level inversely correlated with time below range (glucose <3.9 mmol/L) and time in range (glucose 3.9-10.0 mmol/L) and positively correlated with time above range (glucose >10.0 mmol/L) (Spearman's r=-0.34, -0.25, 0.34, respectively, all P<0.01). Additionally, triglyceride levels had positive correlation with absolute measures of glycemic variability (GV) but not with the coefficient of variation for glucose (Spearman's r=0.12, P>0.05), a relative measure. Multivariate linear regression analysis adjusting for potential confounders including gender, age, disease duration, body mass index (BMI), daily insulin dose, fasting C-peptide, and dyslipidemia medication use showed that higher triglyceride level independently predicted decrease in time below range and time in range and increase in time above range (all P<0.01). Furthermore, interaction analysis found that the interaction between HbA1c and triglyceride was significant in the time below range (P for interaction =0.034). The association between triglyceride and time below range differed substantially after stratification by HbA1c, which was significant in those with HbA1c <7.0% whereas inconsequential among those with HbA1c ≥7.0%. In those with HbA1c <7.0% (n=44), the area under receiver operating characteristic curve of triglyceride predicting achievement of targets of time below range (<4%) was 0.856 (95% confidence interval 0.688-1.000, P=0.042) with an optimal cutoff value of 0.50 mmol/L (sensitivity 100%, specificity 66.7%, positive predictive value 94.4%).
CONCLUSIONS: In adults with T1D, HbA1c may be a potential modifier of the association between triglyceride and time below range, suggesting it might be necessary for those with HbA1c <7.0% accompanied by lower triglyceride levels to set a less intensive glycemic target to minimize risk of hypoglycemia. 2021 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Flash glucose monitoring (FGM); glucose variability; time in ranges; triglyceride; type 1 diabetes (T1D)

Year:  2021        PMID: 33987235      PMCID: PMC8105817          DOI: 10.21037/atm-20-6344

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  37 in total

1.  Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.

Authors:  Melanie Cree-Green; Bryan C Bergman; Eda Cengiz; Larry A Fox; Tamara S Hannon; Kellee Miller; Brandon Nathan; Laura Pyle; Darcy Kahn; Michael Tansey; Eileen Tichy; Eva Tsalikian; Ingrid Libman; Kristen J Nadeau
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

2.  Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent?

Authors:  Louis Monnier; Anne Wojtusciszyn; Nicolas Molinari; Claude Colette; Eric Renard; David Owens
Journal:  Diabetes Care       Date:  2020-01-27       Impact factor: 19.112

3.  Need for Regulatory Change to Incorporate Beyond A1C Glycemic Metrics.

Authors: 
Journal:  Diabetes Care       Date:  2018-06       Impact factor: 19.112

4.  Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects.

Authors:  Sang-Man Jin; Tae-Hun Kim; Ji Cheol Bae; Kyu Yeon Hur; Myung-Shik Lee; Moon-Kyu Lee; Jae Hyeon Kim
Journal:  Diabetes Res Clin Pract       Date:  2014-02-22       Impact factor: 5.602

5.  Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

Authors:  N J Morrish; S L Wang; L K Stevens; J H Fuller; H Keen
Journal:  Diabetologia       Date:  2001-09       Impact factor: 10.122

6.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.

Authors:  Roy W Beck; Richard M Bergenstal; Tonya D Riddlesworth; Craig Kollman; Zhaomian Li; Adam S Brown; Kelly L Close
Journal:  Diabetes Care       Date:  2018-10-23       Impact factor: 19.112

7.  Development and Validation of a Method to Estimate Insulin Sensitivity in Patients With and Without Type 1 Diabetes.

Authors:  Lindsey M Duca; David M Maahs; Irene E Schauer; Bryan C Bergman; Kristen J Nadeau; Petter Bjornstad; Marian Rewers; Janet K Snell-Bergeon
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

8.  Glucose Time In Range, Time Above Range, and Time Below Range Depend on Mean or Median Glucose or HbA1c, Glucose Coefficient of Variation, and Shape of the Glucose Distribution.

Authors:  David Rodbard
Journal:  Diabetes Technol Ther       Date:  2020-02-18       Impact factor: 6.118

9.  Glucose control predicts 2-year change in lipid profile in youth with type 1 diabetes.

Authors:  David M Maahs; Dana Dabelea; Ralph B D'Agostino; Jeannette S Andrews; Amy S Shah; Nancy Crimmins; Elizabeth J Mayer-Davis; Santica Marcovina; Giuseppina Imperatore; R Paul Wadwa; Steven R Daniels; Kristi Reynolds; Richard F Hamman; Lawrence M Dolan
Journal:  J Pediatr       Date:  2012-07-11       Impact factor: 4.406

Review 10.  A View Beyond HbA1c: Role of Continuous Glucose Monitoring.

Authors:  Haleh Chehregosha; Mohammad E Khamseh; Mojtaba Malek; Farhad Hosseinpanah; Faramarz Ismail-Beigi
Journal:  Diabetes Ther       Date:  2019-04-29       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.